The $8 billion all-cash deal gives Genmab full ownership of Merus’ late-stage antibody therapy petosemtamab, which has received two FDA Breakthrough Therapy Designations for head and neck cancer.
Merus’ cancer drug petosemtamab, developed for head and neck tumors, has shown stronger results than the current standard of care and is projected to top $1 billion in annual sales by 2030.